Clinical trials on ICIs in gynecological malignancies

Disease Setting ICIs
CTLA-4 PD-1 PD-L1
Ipilimumab
Tremelimumab
Pembrolizumab
Nivolumab
Dostarlimab
Cemiplimab
Ave
Atezolizumab
Durvalumab
OC NACT first-line ENGOT OV 43 [60]
FIRST [61]
ATHENA [62]
MITO 28 [63]
AGO DUO [59]
ROC Plat Se NRG-GY003 [53] NCT02873962 [77] ANITA [79]
ATALANTE [80]
ROC Plat R NCT02440425 [52]
NCT02873962 [74]
EORTC 1508 [81]
NCT02484404 [82]
EC Advanced (III-IV) recurrent CT naive LEAP-001 [41]
NRG-GY018 [45]
MITO END-3 [44]
ATTEND [42]
RUBY [43]
Recurrent prior CT NCT03015129 [37]
NCT02982486 [40]
NCT02834013 [73]
NCT02899793 [38]
KEYNOTE-775 [46]
NCT02549209 [45]
MITO END-3 [44]
ATTEND [42]
NCT02912572 [39]
NCT03526432 [83]
CC LACC NCT01711515 [74] MITO CERV 3 [15]
NCT04221945 [14]
Recurrent metastatic NRG-GY002 [75]
KEYNOTE-826 [16]
REGENERON [19]
CX 8 [76]
NCT02921269 [78]
BEAT [17]

NACT: neoadiuvant chemotherapy; ROC: recurrent epithelial ovarian cancer; Plat Se/Plat R: platinum sensitive/resistant; LACC: locally advanced cervical cancer